Esperion Therapeutics Files 8-K, Confirms NASDAQ Listing

TL;DR

**ESPR filed an 8-K, confirming its NASDAQ listing and regulatory compliance.**

AI Summary

Esperion Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 10, 2024. This filing indicates that the company's Common Stock, with a par value of $0.001 per share, is registered on the NASDAQ Stock Market LLC under the trading symbol ESPR. This matters to investors because it confirms the company's continued compliance with SEC reporting requirements and its listing on a major exchange, providing transparency and liquidity for shareholders.

Why It Matters

This filing confirms Esperion Therapeutics' ongoing compliance with SEC regulations and its active listing on the NASDAQ, which is crucial for investor confidence and stock liquidity.

Risk Assessment

Risk Level: low — This filing is routine and primarily confirms existing information, posing minimal new risk.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the company's operational status and exchange listing, but it doesn't provide new financial or operational insights for immediate action.

Key Numbers

• $0.001 — Par value per share (This is the nominal value assigned to each share of Esperion Therapeutics' Common Stock.)

Key Players & Entities

• Esperion Therapeutics, Inc. (company) — the registrant filing the 8-K
• NASDAQ Stock Market LLC (company) — the exchange where Esperion's common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock
• January 11, 2024 (date) — date of filing the 8-K
• January 10, 2024 (date) — date of earliest event reported

Forward-Looking Statements

• Esperion Therapeutics will continue to maintain its listing on the NASDAQ Stock Market LLC. (Esperion Therapeutics, Inc.) — high confidence, target: 2025-01-10

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
• $45 million — nses are expected to be in the range of $45 million to $55 million; (ii) selling, general a
• $55 million — ed to be in the range of $45 million to $55 million; (ii) selling, general and administrati
• $180 — nses are expected to be in the range of $180 to $190 million; and (iii) operating ex
• $190 million — expected to be in the range of $180 to $190 million; and (iii) operating expenses are expec
• $225 million — nses are expected to be in the range of $225 million to $245 million. Selected slides from t
• $245 million — d to be in the range of $225 million to $245 million. Selected slides from the Company's pre

Filing Documents

• espr-20240110.htm (8-K) — 29KB
• jpmslides.htm (EX-99.1) — 2KB
• jpm1.jpg (GRAPHIC) — 107KB
• jpm2.jpg (GRAPHIC) — 179KB
• jpm3.jpg (GRAPHIC) — 77KB
• 0001628280-24-001163.txt ( ) — 656KB
• espr-20240110.xsd (EX-101.SCH) — 2KB
• espr-20240110_lab.xml (EX-101.LAB) — 24KB
• espr-20240110_pre.xml (EX-101.PRE) — 13KB
• espr-20240110_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 10, 2024, Esperion Therapeutics, Inc. (the "Company") announced in its management presentation at the 42 nd Annual J.P. Morgan Healthcare Conference the following financial guidance for the fiscal year ending December 31, 2024, which guidance is based on management's current expectations for the business: (i) research & development expenses are expected to be in the range of $45 million to $55 million; (ii) selling, general and administrative expenses are expected to be in the range of $180 to $190 million; and (iii) operating expenses are expected to be in the range of $225 million to $245 million. Selected slides from the Company's presentation are attached as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company's expected full year expenses and financial performance. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward- looking statements are qualified in their entirety by reference to the factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and in the Company's other reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Slides from Presentation of the Company, dated January 10, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 11, 2024 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR